This kit is intended for the quantitative determination of human alpha-fetoprotein (hAFP) in maternal serum (during the first and second trimesters of pregnancy) and amniotic fluid (during the second trimester of pregnancy) using the 6000 DELFIA® Xpress clinical random access screening platform.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Products may not be licenced in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.
In unaffected pregnancies the level of hAFP increases rapidly with gestation in maternal serum and decreases in amniotic fluid. Fetal open neural wall defects result in a marked elevation in amniotic fluid levels and a smaller but substantial increase on average in maternal serum levels, particularly at 16-18 weeks. Maternal serum hAFP can be used in screening for neural tube and abdominal wall defects. In contrast, the level is reduced by about one-quarter, on average, in pregnancies affected by Down''s syndrome and can be used as part of multi-marker second trimester screening programmes including free hCGb or intact hCG, with or without unconjugated estriol (uE3) and inhibin A. Maternal serum levels are also reduced on average in pregnancies affected by Edwards'' syndrome. This solid phase, two-site fluoroimmunometric assay is based on the direct sandwich technique in which two monoclonal antibodies are directed against two separate antigenic determinants on the hAFP molecule. The analytical sensitivity is typically better than 0.1 U/mL. All Wallac diagnostic products may not be available in certain countries. For information on availability please contact your local representative.
|Detection Method||Time-Resolved Fluorescence (TRF)|
|Product Brand Name||DELFIA® Xpress|
|Unit Size||96 assays|